Ligand Pharmaceuticals
LGND· Manufacturing· Fiscal year ends in December
CEO pay in FY2025Stock +76.5% in FY2025
Todd C. Davis is the CEO of Ligand Pharmaceuticals and was paid $11.5M in FY2025 (Dec), down 11%.
Pay$100 in the stock at the end of FY21 → $122
Executives3
See all- 1Todd C. DavisChief Executive OfficerFY2025
- 2Tavo EspinozaChief Financial OfficerFY2025
- 3Andrew ReardonChief Legal Officer and SecretaryFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allLigand Pharmaceuticals paid its 3 named executives $19.6M in total in FY2025 (Dec). CEO Todd C. Davis was paid $11.5M of that.
| Name | |||
|---|---|---|---|
| Todd C. DavisChief Executive Officer | |||
| Tavo EspinozaChief Financial Officer | |||
| Andrew ReardonChief Legal Officer and Secretary |
of each named executive, from the Summary Compensation Table of each proxy.
Peers18
See all
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.
Activity
Filings6
See all| Proxy statement | DEF 14A | Apr 21, 2026 | FY2025 |
| Annual report | 10-K | Feb 27, 2026 | FY2025 |
| Proxy statement | DEF 14A | Apr 22, 2025 | FY2024 |
| Annual report | 10-K | Feb 28, 2025 | FY2024 |
| Proxy statement | DEF 14A | Apr 25, 2024 | FY2023 |
| Annual report | 10-K | Feb 29, 2024 | FY2023 |
